NCT07675421 Impact of HMB Supplementation on Inflammation and Outcomes in Head and Neck Cancer
| NCT ID | NCT07675421 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Federal University of Minas Gerais |
| Condition | Head and Neck Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2026-08-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer patients undergoing surgery are at high risk of malnutrition due to the effects of the tumor and surgical stress, which can lead to worse clinical outcomes. This study aims to evaluate the impact of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on inflammatory markers and clinical outcomes in patients with malignant tumors of the upper airways and digestive tract undergoing surgery. This is a randomized, double-blind clinical trial. Participants will be randomly assigned to one of two groups: intervention (3 g/day of HMB) or control (3 g/day of maltodextrin) for 30 days prior to surgery. Initial assessments will include nutritional status, muscle strength, quadriceps muscle thickness by ultrasound, and laboratory tests. Postoperative clinical outcomes will be monitored through electronic medical records.
Eligibility Criteria
Inclusion Criteria: * Individuals aged 18 years or older; * Both sexes (male and female); * Patients treated at the outpatient clinic for head and neck carcinoma; * Indication for potentially curative tumor resection surgery. Exclusion Criteria: * Diagnosis of cancer of the face, skin, paranasal sinuses, or thyroid; * Undergoing neoadjuvant or palliative treatment; * Cognitive or intellectual impairment that may hinder proper understanding of the study; * Refusal to participate or to sign the informed consent form.
Contact & Investigator
Marcus Vinícius M Andrade, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Medicine, Federal University of Minas Gerais
Frequently Asked Questions
Who can join the NCT07675421 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07675421 currently recruiting?
Yes, NCT07675421 is actively recruiting participants. Contact the research team at andrademufmg@gmail.com for enrollment information.
Where is the NCT07675421 trial being conducted?
This trial is being conducted at Belo Horizonte, Brazil.
Who is sponsoring the NCT07675421 clinical trial?
NCT07675421 is sponsored by Federal University of Minas Gerais. The principal investigator is Marcus Vinícius M Andrade, MD, PhD at Department of Medicine, Federal University of Minas Gerais. The trial plans to enroll 66 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.